Trimethoprim-Sulfamethoxazole Compared with Ampicillin in Acute Infectious Exacerbations of Chronic Bronchitis: A Double-Blind, Crossover Study

Chodosh, Sanford; Eichel, Bertram; Ellis, Charles D.; Tc, Medici; Fating, L. Jack

doi:10.1093/infdis/128.supplement_3.s710

Cited by 14 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That investigation gave grounds for our belief, since confirmed by many works, in the value of co-trimoxazo1e for this indication (7)(8)(9)(10)(11)(12).…”

Section: Bibliographysupporting

confidence: 73%

“…The value of oral co-trimoxazole in respiratory infections has been well established, as evidenced by many control studies (7)(8)(9)(10)(11)(12). This comparative clinical trial of co-trimoxazole in parenteral form also demonstrates its value in serious respiratory infections that require a parenterally administered antibiotic drug.…”

Section: Discussionmentioning

confidence: 95%

“…In vitro susceptibility studies to amphotericin B and 5-FC were performed as previously described (12,13). Resistance was defined as a minimal inhibitory concentration (MIC) ).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Parasites, Fungi, and Viruses

Geddes¹,

Williams²

1976

View full text Add to dashboard Cite

“…That investigation gave grounds for our belief, since confirmed by many works, in the value of co-trimoxazo1e for this indication (7)(8)(9)(10)(11)(12).…”

Section: Bibliographysupporting

confidence: 73%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Parasites, Fungi, and Viruses

Geddes¹,

Williams²

1976

View full text Add to dashboard Cite

“…However, the expectation, based on our earlier report [9], that TMP-SMZ might be more efficacious than ampicillin was not realized. Various ratios of TMP and SMZ employed by other investigators have been found to be comparable or superior to other commonly used antibiotics for the treatment of acute bacterial bronchitic exacerbations.…”

Section: Discussionmentioning

confidence: 89%

Comparison of Trimethoprim-Sulfamethoxazole with Ampicillin in Acute Infectious Exacerbations of Chronic Bronchitis: A Double-Blind Crossover Study

Chodosh¹,

Eichel²,

Ellis³

et al. 1982

Clinical Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Two separate acute bacterial exacerbations of chronic bronchitis or chronic asthmatic bronchitis were treated in 20 patients in a double-blind crossover study. One course of treatment consisted of 320 mg of trimethoprim (TMP) plus 1,600 mg of sulfamethoxazole (SMZ) daily and the other of 2 g of ampicillin daily; each drug was given for 14 days. Patients were observed initially, twice a week during therapy, and weekly after therapy. Observations that were recorded included graded chest symptoms and physical findings, vital signs, pulmonary function, hematologic parameters, and objective sputum measurements (daily volume, purulence, differential quantitative cytology, quantitative bacterial counts, physical properties, levels of lactate dehydrogenase with its isoenzymes, levels of myeloperoxidase, and presence of deoxyribonucleic acid fibers). Both antibiotic regimens were effective in resolving these acute bacterial exacerbations. Paired z-test analysis revealed few and minor differences between TMP-SMZ and ampicillin during therapy, although three patients did not complete TMP-SMZ therapy because of adverse reactions. However, the period between the two bacterial exacerbations was significantly longer after ampicillin therapy. Innovative in this investigation are the study design and the objective quantitative measurements of inflammatory response and bacterial populations in sputum.Acute bacterial bronchitic exacerbations are important clinical events in chronic bronchitis because of their contribution to morbidity. Although Koch's postulates are difficult to prove in this setting, the overwhelming conclusion based on experience is that treatment with antibiotics is temporally related to clinical recovery. Many antimicrobial agents appear to be effective in treatment of these acute bacterial exacerbations, and trimethoprim-sulfamethoxazole (TMP-SMZ) is among the more recent additions to this list. Like most of these antibiotics, TMP-SMZ has been experimentally demonstrated to be effective in acute bacterial bronchitic exacerbations by means of a limited number of objective measurements in randomly assigned, parallel investigations. To a large extent, the objective criteria of sputum volume, This research was supported by a grant-in-aid from Hoffmann-LaRoche, Inc., Nutley, New Jersey.Please address requests for reprints to Dr. Sanford Chodosh, Sputum Laboratory, ACC Building, Boston City Hospital, 818 Harrison Avenue, Boston, Massachusetts 02118. 517 gross sputum purulence, bacterial culture, pulmonary function, and vital signs are only indirect measures of the infectious process. As such, they lack the preciseness needed for the determination of possible differences between alternative methods of therapy.Methods developed by Chodosh and colleagues have been used to compare the efficacy of various types of antimicrobial therapy in acute bacterial exacerbations of chronic bronchitis. Some of the measurements provide criteria that more closely reflect the level of bronchopulmonary inflammation and the size of bact...

show abstract

“…Sulfamethoxazole (SM) combined with trimethoprim (TM) is widely used, especially in the treatment of urinary infections [2,4,7]. A fixed combination is very popular in several countries, and even one half of all chemotherapy has been reported as having occurred by using this combi nation [19].…”

Section: Introductionmentioning

confidence: 99%

Sulfadiazine-Trimethoprim Combination in the Treatment of Urinary Tract Infections

1977

View full text Add to dashboard Cite

In a clinical double-blind study on 198 patients with a urinary tract infection, no differences were found between comparable groups treated with either sulfadiazine (SD) 1,000 mg/trimethoprim (TM) 320 mg or sulfamethoxazole (SM) 1,600 mg/trimethoprim 320 g daily for 2 weeks. The favorable results were obtained according to the bacteriological control in 85 and 79%, respectively. Also the incidence of side effects was the same (22 and 24%, resp.). The number of cases within which the treatment had to be discontinued did not differ percentually, either (6.6 and 8.4%, resp.). Based on the bacteriological sensitivity tests and the clinical trial, the authors conclude that TM can be combined with SD as well as with SM. Pharmacokinetic advantages, like a lower protein-binding and a lesser metabolism, may even make SD more preferable.

show abstract

Trimethoprim-Sulfamethoxazole Compared with Ampicillin in Acute Infectious Exacerbations of Chronic Bronchitis: A Double-Blind, Crossover Study

Cited by 14 publications

References 5 publications

Parasites, Fungi, and Viruses

Parasites, Fungi, and Viruses

Comparison of Trimethoprim-Sulfamethoxazole with Ampicillin in Acute Infectious Exacerbations of Chronic Bronchitis: A Double-Blind Crossover Study

Sulfadiazine-Trimethoprim Combination in the Treatment of Urinary Tract Infections

Contact Info

Product

Resources

About